The Patent Finder

Sphingotec GmbH

16 patents currently held · Updated Nov 21, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 15, 2027
    The maintenance fee for Adrenomedullin assays and methods for determining mature adrenomedullin (US 11,726,101) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Selenoprotein P for prediction of a first cardiovascular event (US 11,844,812) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 2 fees due Sep 24 to 30, 2027 · next Sep 24

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 12,228,581Adrenomedullin assays and methods for determining mature andrendomedullin
In force
 · USPTO record
In forceUSPTO record
US 12,247,988Adrenomedullin assays and methods for determining mature andrendomedullin
In force
 · USPTO record
In forceUSPTO record
US 11,726,101Adrenomedullin assays and methods for determining mature adrenomedullin
In force
 · USPTO record
In forceUSPTO record
US 9,535,060Adrenomedullin assays and methods for determining mature adrenomedullin
In force
 · USPTO record
In forceUSPTO record
US 9,664,695Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
In force
 · USPTO record
In forceUSPTO record
US 9,702,876Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female Subject
In force
 · High confidence
In forceHigh confidence
US 10,114,029Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
In force
 · USPTO record
In forceUSPTO record
US 11,016,107Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
In force
 · USPTO record
In forceUSPTO record
US 12,399,186Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
In force
 · USPTO record
In forceUSPTO record
US 10,598,674Adrenomedullin to guide therapy of blood pressure decline
In force
 · USPTO record
In forceUSPTO record
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents
Also on record, not counted in the 16: 4 patents in force now held by others · 7 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 2 abandoned · 14 no status recorded

Showing 1 to 10 of 24, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/148,633Treatment of Dementia or Alzheimer's an Anti-Adrenomedullin (ADM) Antibody or an Anti-Adrenomedullin Antibody FragmentDec 30, 2022Pending
17/955,765Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female SubjectSep 29, 2022Pending
18/568,334A Method for Predicting Sepsis and Septic ShockJun 17, 2022Pending
18/289,612May 6, 2022No status recorded
17/201,518Pro-Adrenomedullin or Fragment Thereof in Patients Infected with Corona Virus and Treatments with Binder Against AdrenomedullinMar 15, 2021Pending
17/131,008Method for Predicting the Risk of Getting Cancer or Diagnosing Cancer in a Female SubjectDec 22, 2020Pending
17/635,265A Method for Diagnosing or Monitoring Kidney Function or Diagnosing Kidney Dysfunction in Pediatric PatientsAug 14, 2020Pending
16/895,169Jun 8, 2020No status recorded
16/781,226Feb 4, 2020No status recorded
16/748,298Jan 21, 2020No status recorded
10 of 24 applications shown.
Pro members see all 24 published applications.
Pro members: see all 24 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited